Who is sponsoring NCT04156217?

NCT04156217 is sponsored by Hebei Yanda Ludaopei Hospital.

What drugs are being tested in NCT04156217?

Interventions in NCT04156217: EBV-TCR-T cells.

What condition does NCT04156217 study?

NCT04156217 studies EBV Emia and EBV Positive PTLD After Allogenic HSCT.

Is NCT04156217 still recruiting?

NCT04156217 is currently completed. Last updated 8 March 2022.

Last reviewed 2022-03-08 · How we verify

NCT04156217

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

EBV-TCR-T Cells for EB Virus Infection After HSCT

Completed Phase 1 Last updated 8 March 2022

What this trial tests

Phase 1 trial testing EBV-TCR-T cells in EBV Emia and EBV Positive PTLD After Allogenic HSCT in 18 participants. Completed in 31 October 2021.

Timeline

10 February 2020

Primary endpoint
30 July 2021

31 October 2021

Quick facts

Lead sponsor	Hebei Yanda Ludaopei Hospital
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	10 February 2020
Primary completion	30 July 2021
Estimated completion	31 October 2021
Sites	1 location across China

Drugs / interventions tested

EBV-TCR-T cells — full drug profile →

Conditions studied

EBV Emia and EBV Positive PTLD After Allogenic HSCT — all drugs for EBV Emia and EBV Positive PTLD After Allogenic HSCT →

Sponsor

Hebei Yanda Ludaopei Hospital

Who can join

Adults 1 to 70, any sex, with EBV Emia and EBV Positive PTLD After Allogenic HSCT. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of EBV-TCR-T cells in patients with EB virus infection after HSCT.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Redirecting T Cells against Epstein-Barr Virus Infection and Associated Oncogenesis.
Münz C. · · 2020 · cited 28× · PMID 32512847 · DOI 10.3390/cells9061400
Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas.
Pei Y, Wong JHY, Robertson ES. · · 2020 · cited 24× · PMID 32916819 · DOI 10.3390/cancers12092565
TCR-T cell therapy for solid tumors: challenges and emerging solutions.
He W, Cui K, Farooq MA, Huang N, et al · · 2025 · cited 10× · PMID 40129944 · DOI 10.3389/fphar.2025.1493346
Virus-specific T cells for malignancies - then, now and where to?
Sharma S, Leung WK, Heslop HE. · · 2020 · cited 6× · PMID 33738181 · DOI 10.1007/s40778-020-00170-6
Harnessing Cellular Immunotherapy for EBV-Associated Malignancies: Current Advances and Future Directions.
Gao Y, Wang D, Li C. · · 2025 · cited 2× · PMID 40401927 · DOI 10.1111/jcmm.70603

Verify or expand the search:

Other trials of EBV-TCR-T cells

Trials testing the same drug.

NCT06119256 — Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT · Phase 1 · recruiting
NCT06135922 — Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection · Phase 1 · recruiting

Other Hebei Yanda Ludaopei Hospital trials

Trials by the same sponsor.

NCT05590091 — Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients · NA · unknown
NCT05518357 — LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia · Phase 1 · completed
NCT04508842 — CD19/CD22-Dual-STAR-T for Patients With B Cell Acute Leukemia(B-ALL) · Phase 1 · terminated
NCT04260945 — CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients · Phase 1 · completed
NCT04260932 — CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04156217 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hebei Yanda Ludaopei Hospital
Last refreshed: 8 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04156217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing